AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Guidelines support AFINITOR® when a patient's VEGF**-targeted therapy fails
AFINITOR® received the highest Category of recommendation from the NCCN, which endorses it as the only Category 1 treatment following a first-line VEGF-TKI (e.g. sunitinib or sorafenib)
The National Comprehensive Cancer Network (NCCN) has added AFINITOR to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors. According to NCCN Guidelines AFINITOR is the first and only Category 1 treatment option after initial VEGF TKI failure.1
Learn more about the latest NCCN Guidelines click here.
EAU Guidelines grant AFINITOR® the highest Category of recommendation
The European Association of Urology (EAU) Guidelines on renal cell carcinoma endorse AFINITOR as the only grade A treatment for second-line therapy after failure of a VEGF-targeted therapy.2
EORTC recommends AFINITOR® as agent of choice for patients whose disease has progressed after a TKI
The European Organization for Research and Treatment of Cancer (EORTC) group opinion on metastatic renal cell carcinoma recommends AFINITOR for patients whose disease has progressed on a tyrosine kinase inhibitor.3
ESMO group recommends AFINITOR® for patients after progression on a VEGF TKI
The European Society for Medical Oncology (ESMO) working group, in their clinical recommendations for treatment of renal cell carcinoma, granted AFINITOR a recommendation for use in patients after progression on a VEGF TKI. AFINITOR use in this patient population was named “standard” by the committee, with no recommendation for any other option.4
Next: Patient Profiles
**VEGF: vascular endothelial growth factor
References:
1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Kidney Cancer. V.2.2009. http//www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 14, 2009.
2. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PFA, Patard JJ, Sinescu IC. Guidelines on Renal Cell Carcinoma. European Association of Urology, 2009.
3. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M.Eur J Cancer. 2009 Mar;45(5):765-73. Epub 2009 Jan 20. Review.
4. Bellmunt J.Future developments in renal cell carcinoma.Ann Oncol. 2009 May;20 Suppl 1:i13-17.
